Press Releases August 26, 2026 04:15 PM

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

RxSight to Present at the Wells Fargo Healthcare Conference in September 2026

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
RXST

RxSight, Inc., a NASDAQ-listed ophthalmic medical device company, announced that its management will participate in the Wells Fargo Healthcare Conference, presenting the company's vision correction technology involving the Light Adjustable Lens system.

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
RXST
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • RxSight is scheduled to present at a major healthcare investor conference, increasing visibility among institutional investors.
  • The company's Light Adjustable Lens system offers a unique post-surgery adjustable intraocular lens for cataract patients, representing an innovative ophthalmic medical device.
  • The presentation will be webcast live and archived, enhancing accessibility for investors and stakeholders.

ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company’s investor relations website at https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com


Risks

  • Market adoption of the Light Adjustable Lens technology could be slower than anticipated, impacting revenue growth.
  • Competition from other ophthalmic device manufacturers in the cataract surgery segment may pressure market share.
  • Regulatory or reimbursement challenges remain potential uncertainties affecting commercialization and sales momentum.

More from Press Releases

Rogers and Quebecor Agree to New 12-Year Sublicensing Deal for National NHL Games in French Sep 3, 2026 Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 Sep 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences Sep 3, 2026 Root to Participate in Upcoming Investor Conferences Sep 3, 2026 Weatherford Shareholders Approve Redomestication to Delaware Sep 3, 2026